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Letter to the EditorResponse to J-Y. Maillard: Are
amine-only-containing products
sporicidal?Sir,
J-Y. Maillard made a very important point in reflecting that,
during efficacy testing of disinfectants, demonstration of
neutralization of the biocidal effect at the end of contact time
is crucial. We also agree that ‘It is thus puzzling and possibly
concerning that products containing amines alone are being
used as sporicides in healthcare settings’ [1].
As referenced by Maillard, resistance of bacterial spores is
intrinsic and is based on structural properties, such as the core
protecting the bacterial spore from chemical or physical
damage [1]. In this context, Steward points to the specific
differences of the exosporium layer in different spore-forming
bacteria [2]. In general, bacteria of the phylum Firmicutes use
spore formation as a survival mechanism to persist in the
environment even under unfavourable conditions. Phyloge-
netically, the phylum Firmicutes includes aerobic bacterial
species, such as Bacillus spp., as well as anaerobic species such
as Clostridium spp. Whereas an exosporium layer has been
clearly identified for Bacillus cereus and Bacillus anthracis, it is
lacking in Bacillus subtilis. Regarding the anaerobic spore-
forming bacterium Clostridium difficile, no clear evidence
for an exosporium layer was found by Stewart and the exis-
tence of a crust layer was hypothesized [2].
Thus, when discussing sporicidal efficacy in the healthcare
setting it becomes clear that differentiation regarding aeti-
ology, clinical prevalence, and morphological characteristics
needs to be considered. Only a few reports for B. cereus, and
no reported outbreak in the clinical setting have been found in
the literature for the aerobic spore-forming bacterium
B. subtilis, indicating the inferior role of aerobic spore-forming
bacteria in the healthcare setting [3e5]. However, numerous
reports of C. difficile outbreaks exist, and C. difficile is
regarded as a well-established pathogen worldwide [6]. Thus,
there is a need to provide the healthcare setting with spori-
cides that have been tested under reliable and robust test
conditions, specifically targeting C. difficile as the most
important pathogen in the clinical environment.
Reflecting the need of hygienic prevention measures to fight
spore-forming C. difficile, we wish to point out that justrecently a European standard for sporicidal testing of disin-
fectants in the healthcare area has been proposed by the Eu-
ropean standards committee CEN/TC 216 working group 1 as a
prEN and will be published in autumn 2018 as EN 17126 [7]. This
standard is perfectly in line with the author’s view ‘that a
sporicide should kill 103 to 106 spores’; the pass criterion for
this standard is a 4 log10 reduction in spores of C. difficile. In
addition, a strain of particular clinical relevance (ribotype 027)
has been chosen as a test organism of this standard. This strain
has been demonstrated to be less susceptible to disinfectants,
when compared to other type strains of this species [8].
Reflecting the state of the art, prevention measures in the
clinical setting should therefore include disinfectants with a
proven efficacy against C. difficile spores according to the
proposed standard.
We would like to encourage the author and all interested
and other knowledgeable experts to join the standards com-
mittee and contribute to the further development of an
appropriate state of the art.
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